List of investigational sexual dysfunction drugs

This is a list of investigational sexual dysfunction drugs, or drugs that are currently under development for clinical use for the treatment of sexual dysfunction but are not yet approved. Sexual function disorders include anorgasmia, atrophic vaginitis (vaginal atrophy), decreased libido, dyspareunia (painful sexual intercourse), erectile dysfunction, female sexual dysfunction (female sexual arousal disorder (FSAD)/hypoactive sexual desire disorder (HSSD)), male sexual dysfunction, premature ejaculation, vulvodynia (vulva pain), paraphilias, and hypersexuality, among others.

Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses. The format of list items is "Name (Synonyms) – Mechanism of Action – Indication [Reference]". The section that the drug is in corresponds to its highest developmental phase, not its phase for all listed indications.

This list was last comprehensively updated in January 2026. It is likely to become outdated with time.

Under development

Preregistration

  • Orenetide (BP-101; BP101; Libicore; Desirix) – undefined mechanism of action (synthetic small peptide) – female sexual dysfunction [1] [2][1][2][3][4]
  • Tadalafil oral film (AQST-119; Exordia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [3]
  • Tadalafil oral film (Exordia; INT-007; INT0007; INT0007/2006) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [4]

Phase 3

  • Clomipramine/sildenafil (CDFR-0812) – combination of clomipramine (tricyclic antidepressant (TCA), serotonin–norepinephrine reuptake inhibitor (SNRI), other actions) and sildenafil (phosphodiesterase PDE5 inhibitor) – premature ejaculation [5]
  • Gepirone (Ariza; BMY-13805-1; BMY-13805; Exxua; Gepirone ER; MJ-13805; Org-33062; TGFK07AD; Travivo; Variza) – serotonin 5-HT1A receptor agonist, other actions – decreased libido [6]
  • Nitroglycerin gel (Eroxon; glyceryl trinitrate topical gel; MED-2001; MED-2003; MED-2004; MED-2005; MED-3000; MED2002) – guanylate cyclase stimulant, nitric oxide donor, nitric oxide stimulant – erectile dysfunction [7]
  • Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – decreased libido [8]
  • Sacubitril/valsartan (AHU-377/valsartan; Enrest; Enresuto; Entresto; Entresto Sprinkle; LCZ-696; LCZ-696A; Neparvis; valsartan/AHU-377; valsartan/sacubitril) – combination of sacubitril (neprilysin inhibitor) and valsartan (angiotensin II receptor type 1 (AT1) antagonist) – erectile dysfunction [9]

Phase 2

  • Aildenafil (methisosildenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [10]
  • AN-788 (IP-2018; IP2018; NSD788; NSD-788) – serotonin–dopamine reuptake inhibitor (SDRI) – erectile dysfunction [11]
  • Apomorphine intranasal (AL-101; intranasal apomorphine) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [12]
  • Autologous mesenchymal stem cell therapy (autologous bone marrow-derived mesenchymal stem cell therapy; Cellgram; Cellgram-ED; Cellgram-LC; Cerecellgram-spine; Hearticellgram-AMI; Immunocellgram; Impocellgram; Livercellgram; Lungcellgram; MSC-1; MSC-2) – cell replacement – erectile dysfunction [13]
  • Botulinum toxin A (AboBoNT-A; AbobotulinumtoxinA; Alluzience; Azzalure; BoNT-A; BTX-A-HAC; BTX-A-HAC NG; Clostridium botulinum toxin type A haemagglutinin complex; Dysport; Dysport NG; Dysport RU; Dysport Solution; Dysport Next Generation; Reloxin) – acetylcholine release inhibitor and neuromuscular blocking agent – vulvodynia [14]
  • Bupropion/trazodone (Lorexys; Orexa; S1P-104; S1P-205; SIP-104; trazodone/bupropion) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), other actions) and trazodone (serotonin antagonist and reuptake inhibitor (SARI), various actions) – erectile dysfunction, female sexual dysfunction, male sexual dysfunction [15]
  • Buspirone/testosterone (Lybridos; testosterone/buspirone) – combination of buspirone (serotonin 5-HT1A receptor agonist, other actions) and testosterone (androgen) – female sexual dysfunction [16]
  • BZ-371A (PnPP-19) – nitric oxide stimulant – erectile dysfunction, female sexual dysfunction [17]
  • Cligosiban (IX-01; PF-3274167) – oxytocin receptor antagonist – premature ejaculation [18]
  • Estetrol (Donesta; E4) – estrogen (estrogen receptor agonist) – atrophic vaginitis, female sexual dysfunction [19]
  • Estriol vaginal ring (VR-102; VR102; long-acting estriol vaginal ring) – estrogen (estrogen receptor agonist) – atrophic vaginitis [20]
  • Fadanafil (XZP-5849) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [21]
  • FKW-00GA (FKW00GA; TGW-00AA; TGW00AA; TGWOOAA; TGW-OOAA) – serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist – sexual function disorders [22]
  • LIB-01 (DIC-2024; DIC2024; Libiguin) – indirect melanocortin MC4 receptor potentiator – erectile dysfunction, premature ejaculation [23]
  • Onabotulinum toxin A (BoNTA; Botox; botulinum toxin A injectable; GSK-1358820; GSK1358820; OnabotA X; OnabotulinumtoxinA X; Vistabel; Vistabex) – acetylcholine release inhibitor and neuromuscular blocking agent – premature ejaculation [24]
  • OPK-88004 (LY-2452473; TT701) – selective androgen receptor modulator (SARM) – erectile dysfunction [25]
  • Pudafensine (IP2015; IP-2015) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – erectile dysfunction, vulvodynia, female sexual dysfunction [26]
  • Sildenafil/testosterone (Lybrido; testosterone/sildenafil) – combination of sildenafil (phosphidiesterase PDE5 inhibitor) and testosterone (androgen) – female sexual dysfunction [27]
  • Sildenafil topical – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [28]
  • Testosterone intranasal (low-dose) (MPP-14; Noseafix; TBS-2; Tefina) – androgen (androgen receptor agonist) – anorgasmia, decreased libido [29]
  • TGFK-09SD (TGFK09SD) – serotonin 5-HT1A receptor agonist – female sexual dysfunction [30]

Phase 1/2

  • Mirabegron (Betanis; Betmiga; Betmiga PR; Myrbetriq; Myrbetriq Granules; YM-178) – β3-adrenergic receptor agonist – erectile dysfunction [31]

Phase 1

  • KH-001 (KH001) – atypical selective serotonin reuptake inhibitor (SSRI), phosphodiesterase (PDE) inhibitor (purified Sceletium tortuosum (kanna) alkaloid; possibly mesembrine) – premature ejaculation [32][5][6][7]
  • VV-913 (VV913) – undefined mechanism of action – premature ejaculation [33]

Clinical phase unknown

  • Sildenafil orally-dissolving film (NAL8238; NAL-8238; sildenafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [34]
  • Tadalafil orally-dissolving film (NAL8233; NAL-8233; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [35]

Preclinical

  • CF-602 – adenosine A3 receptor modulator – erectile dysfunction [36]
  • S1B-307 – "central nervous system modulator" – anorgasmia, female sexual dysfunction [37]
  • S1B-408 – undefined mechanism of action – anorgasmia [38]
  • S1B-3006 (S1B0-3006; S1B3006) – "central nervous system modulator" – sexual function disorders [39]

Phase unknown

  • Pirenzepine topical (topical pirenzepine; WST-057; WST-1; WST01; WST1/analgesic; WST57) – muscarinic acetylcholine M1 receptor antagonist – sexual function disorders [40]

Not under development

No development reported

  • AB-101 (RJ-101) – undefined mechanism of action – female sexual dysfunction [41]
  • Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [42]
  • Armodafinil ((R)-modafinil; D-modafinil; NH-02D; NH02D) – atypical dopamine reuptake inhibitor (DRI) – premature ejaculation [43] [44][8]
  • Deuterated testosterone (d3-testosterone) – androgen (androgen receptor agonist) – female sexual dysfunction [45]
  • Epelsiban (GSK557296; GSK-557296) – oxytocin receptor antagonist – premature ejaculation [46]
  • Estradiol/testosterone topical gel (LibiGel-E/T; testosterone/estradiol topical gel) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [47]
  • Fibroblast growth factor 1 (FGF-1; FGF1; Acidic FGF; aFGF; Cardio Vascu-Grow; CVBT-141P ; CVBT-141S; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141ED; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141); VT-141D; VT-141ED; VT-141P; VT-141S) – fibroblast growth factor receptor (FGFR) agonist – erectile dysfunction [48]
  • FKK-01PD (FKK-01PD; TGHW-01AP; TGHW01AP) – non-selective dopamine receptor agonist, other actions (apomorphine prodrug) – erectile dysfunction [49]
  • GSK-958108 (GSK958108) – serotonin 5-HT1A receptor antagonist – premature ejaculation [50]
  • HCP-1302 (HCP1302) – undefined mechanism of action – erectile dysfunction [51]
  • Lidocaine topical gel – sodium channel blocker, local anesthetic – dyspareunia [52]
  • PTL-2015 – undefined mechanism of action – erectile dysfunction [53]
  • Research programme: nerve-targeted gene therapy - Periphagen (NC-3; NE-2; NE2-Endomorphin; NG-2; NG2-GAD; NN1-Neurotrophin) – various actions – erectile dysfunction [54]
  • Research programme: sexual dysfunction therapy - Palatin Technologies (PL-6983) – melanocortin receptor modulators – erectile dysfunction, female sexual dysfunction [55]
  • Sildenafil (KW-25084) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [56]
  • Sildenafil orally soluble film (CURE-5003; CUREfilm Blue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [57]
  • Sildenafil oral spray (Duromist; NVD-401; SUD-003; SUD-004; SUDA-004; Sudamist) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [58]
  • Tadalafil dry powder inhalation (Tadalafil Technosphere) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [59]
  • Tadalafil orodispersible film tablet (Caliberi) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [60]
  • Tadalafil topical (Extrinsa) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [61]
  • Tadalafil/tamsulosin – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [62]
  • Tunodafil (ecocarbamate; gluconocin; yonkenafil) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [63]
  • Vilazodone (EMD-68843; SB-659746A; Viibryd) – serotonin reuptake inhibitor (SRI), serotonin 5-HT1A receptor agonist – sexual function disorders [64]
  • Zotarolimus (ABT-578; Endeavor; Endeavor Resolute; MDT-4107 DES; Resolute DES; Resolute Integrity; Resolute Onyx; ZoMaxx) – FK-binding protein 12 (FKBP12) ligand and mechanistic target of rapamycin (mTOR) inhibitor – erectile dysfunction [65]

Preregistration submission withdrawal

  • Lasofoxifene (AZU-101; CP-336156; CP-336156-CB; Fablyn; HLX-78; Oporia) – selective estrogen receptor modulator (SERM) – atrophic vaginitis [66]

Suspended

  • Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – female sexual dysfunction [67]

Discontinued

  • Acolbifene/prasterone (dehydroepiandrosterone/acolbifene; DHEA/acolbifene; prasterone/acolbifene; Femivia) – combination of acolbifene (selective estrogen receptor modulator (SERM)) and prasterone (dehydroepiandrosterone; DHEA) (androgen, other actions) – decreased libido [68]
  • Alprostadil SEPA (prostaglandin E1 SEPA; alprostadil/soft enhancement of percutaneous absorption; Topiglan) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [69]
  • Alprostadil/lidocaine (NM02216; NM100061) – combination of alprostadil (prostaglandin E1 (PGE1) agonist) and lidocaine (sodium channel blocker, local anesthetic) – premature ejaculation [70]
  • Amesergide (LY-237733; LY237733; LY-237,733) – serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptor antagonist, other actions – erectile dysfunction, premature ejaculation [71]
  • Apomorphine inhalation (VR-004; VR-040; VR-400) – non-selective dopamine receptor agonist, other actions – erectile dysfunction, female sexual dysfunction [72]
  • Apomorphine intranasal – non-selective dopamine receptor agonist, other actions – erectile dysfunction [73]
  • Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction, premature ejaculation [74]
  • BAY-604552 (BAY98-7081; sGC activator) – guanylate cyclase stimulant – erectile dysfunction [75]
  • Bremelanotide (Rekynda; Vyleesi; PT-141) – melanocortin MC4 receptor agonist – erectile dysfunction [76]
  • CP-866087 (CP-866,087) – μ-opioid receptor antagonist – female sexual dysfunction [77]
  • DA-8031 (DA8031) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [78]
  • Dapoxetine (IMD dapoxetine; YHD-1044) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [79]
  • Delequamine (RS-15385; RS-15385197) – α2-adrenergic receptor antagonist – erectile dysfunction [80]
  • Estradiol/testosterone transdermal (testosterone/estradiol transdermal) – combination of estradiol (estrogen) and testosterone (androgen) – female sexual dysfunction [81]
  • GM-1485 (GPI-1485; NIL-A) – immunophilin modulator – erectile dysfunction [82]
  • Heparin/lidocaine/sodium bicarbonate (alkalised lidocaine and heparin formulation; Hep-Lido-A compounded formulation; U-101; URG-101) – combination of heparin (Factor Xa inhibitor, thrombin inhibitor), lidocaine (sodium channel blocker, local anesthetic), and sodium bicarbonate (absorption enhancer) – dyspareunia [83]
  • hMaxi-K gene therapy (pVAX/hSlo; URO-902) – gene transference – erectile dysfunction [84]
  • INO-1001 (INO1001; Pardex) – poly(ADP-ribose) polymerase inhibitor – erectile dysfunction [85]
  • LGD-2941 (LGD2941; LGD122941; LGD-122941) – selective androgen receptor modulator (SARM) – female sexual dysfunction, male sexual dysfunction [86]
  • Melanotan II (MT-II; PT-14) – melanocortin receptor agonist – erectile dysfunction, male sexual dysfunction [87]
  • Milnacipran (Dalcipran; F-2207; Impulsor; Ixel; Joncia; Midacipran; Midalcipran; Savella; TN-912; Toledomin) – serotonin–norepinephrine reuptake inhibitor (SNRI) – vulvodynia [88]
  • Nitroglycerin topical (Anogesic; Cellegesic; Rectiv; Rectogesic) – nitric oxide donor – dyspareunia, vulvodynia [89]
  • NMI-870 – α2-adrenergic receptor antagonist, nitric oxide donor – erectile dysfunction, female sexual dysfunction [90]
  • Oxytocin (oxytocin gel; oxytocin topical; Vagitocin) – oxytocin receptor agonist – atrophic vaginitis [91]
  • Pagoclone (IP-456; Panex; RP-62955) – GABAA receptor positive allosteric modulator and nonbenzodiazepine/cyclopyrrolone – premature ejaculation [92]
  • PF-446687 (PF-00446687; PF-446,687) – melanocortin MC4 receptor agonist – sexual function disorders [93]
  • PF-592379 (PF-000592379; PF-592,379) – dopamine D3 receptor agonist – erectile dysfunction [94]
  • Research programme: therapeutics - Re-Pharm (RP-0217; RP0217) – protein phosphatase 2A (PP2A) inhibitor – sexual function disorders [95] [96]
  • RO-0282425 (RO0282425) – melanocortin MC4 receptor agonist – erectile dysfunction [97]
  • RTN-001 (KD-027; SLX-2101; SLx-2101) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [98]
  • SAR-407899 (SAR407899; SAR407899A) – Rho-associated kinase inhibitor – erectile dysfunction [99]
  • Sertraline (Aremis; Besitran; CP-51974; CP-51974-01; Gladem; J Zoloft; Lustral; Serad; Serlain; Tatig; Zoloft) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [100]
  • Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [101]
  • Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – female sexual dysfunction [102]
  • Tadalafil sublingual (APC-8000) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [103]
  • Tadalafil/tamsulosin (CKD-397; tamsulosin/tadalafil) – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [104]
  • Tadalafil/tamsulosin (YBH-1603) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [105]
  • Testosterone topical (ESP-210) – androgen (androgen receptor agonist) – female sexual dysfunction [106]
  • Testosterone transdermal (FemTestosterone TDS) – androgen (androgen receptor agonist) – female sexual dysfunction [107]
  • Testosterone transdermal (Luramist; testosterone MDTS; testosterone transdermal spray) – androgen (androgen receptor agonist) – female sexual dysfunction [108]
  • TEMPE (Topical Eutectic Mixture for Premature Ejaculation) – undefined mechanism of action – premature ejaculation [109]
  • UK-357903 (UK-357,903) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [110]
  • UK-390957 (UK-390,957) – serotonin reuptake inhibitor (SRI) – premature ejaculation [111]
  • UK-447841 (UK-447,841) – neprilysin inhibitor – female sexual dysfunction [112]
  • VML-670 (VML670; CEB-1555) – serotonin 5-HT1A receptor agonist – female sexual dysfunction, male sexual dysfunction [113]

Clinically used drugs

Approved drugs

Phosphodiesterase PDE5 inhibitors

  • Avanafil (Razatus; Spedra; Stendra; TA-1790; Zepeed) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [114]
  • Lodenafil (CRIS-031; Helleva) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [115]
  • Mirodenafil (Aibishi; Bravonto; Mvix; SK-3530) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [116]
  • Sildenafil (Revatio; Revatio IV; UK-92480; Viagra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [117]
  • Sildenafil chewable tablets (Nurigra) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [118]
  • Sildenafil orally soluble film (sildenafil ODF; SPO-1101; Vultis) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [119]
  • Sildenafil orally soluble film (orodispersible sildenafil; Please; sildenafil oral dissolving film; sildenafil orally-disintegrating film; sildenafil OSF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [120]
  • Sildenafil oral spray (ASP-001; ASP-002; Bandol; Hezkue) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [121]
  • Sildenafil oro-dispersible tablets (Erecta; FACSID-50) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [122]
  • Simmerafil (Onvita; Onweida; semenafil; TPN-171; TPN-171-H) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [123]
  • Tadalafil (Adcirca; Cialis; GF-196960; IC-351; LY-450190; Zalutia) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [124]
  • Tadalafil oral disintegrating film (SPO-1102; Vulteum; tadalafil ODF) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [125]
  • Tadalafil oral film (OGOOD) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [126]
  • Udenafil (DA-8159; Jurvigo; ME-3113; MZ101; Udzire; WC-3043; WC-3055; Zydena) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [127]
  • Vardenafil (BAY-389456; Levitra; Nuviva; Staxyn; vardenafil ODT; vardenafil orodispersible tablet; Vivanza) – phosphodiesterase PDE5 inhibitor – erectile dysfunction [128]

Prostaglandin E1 (PGE1) agonists

  • Alprostadil (Caverject; Prostaglandin E1) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [129]
  • Alprostadil alfadex (alprostadil alfadex complex; alprostadil-alpha-cyclodextrin; Edex; Prostaglandin E1-α-cyclodextrin complex; Prostandin; Prostavasin; Rigidur; Sugiran; Vasaprostan; Vasoprost; Viridal) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [130]
  • Alprostadil topical (Alprox-TD; Befar; Cold Chain Vitaros; Femprox; RayVa; Room Temperature Vitaros; Virirec; Vitaros; Vytaros; WC-3036) – prostaglandin E1 (PGE1) agonist – erectile dysfunction [131]

Estrogens (estrogen receptor agonists)

  • Conjugated estrogens (conjugated equine estrogens; CEEs; Premarin) – estrogen (estrogen receptor agonist) – atrophic vaginitis, dyspareunia [132]
  • Conjugated estrogens oral (Enjuvia; synthetic conjugated estrogens) – estrogen (estrogen receptor agonists) – atrophic vaginitis [133]
  • Conjugated estrogens/bazedoxifene (Aprela; bazedoxifene acetate/conjugated estrogens; bazedoxifene/conjugated estrogens; bazedoxifene/Premarin; BZA/CE; CE/BZA; conjugated estrogens/bazedoxifene acetate; Duavee; Duavive; Premarin/bazedoxifene; SERM + Premarin) – combination of conjugated estrogens (estrogen) and bazedoxifene (selective estrogen receptor modulator (SERM)) – atrophic vaginitis [134]
  • Estradiol (Estrofem; Innofem; oral estradiol; Vagifem; vaginal estradiol) – estrogen (estrogen receptor agonist) – atrophic vaginitis [135]
  • Estradiol transdermal micro patch (Estradot; Minivelle; Vivelle-Dot) – estrogen (estrogen receptor agonist) – atrophic vaginitis [136]
  • Estradiol vaginal (E2; 17β-estradiol; Estradiol VagiCap; Imvexxy; Joyesta; TX-12-004-HR; TX-004HR; VagiCap; Yuvvexy) – estrogen (estrogen receptor agonist) – atrophic vaginitis [137]
  • Estradiol acetate (Estrace; estradiol acetate intravaginal ring; estradiol acetate IVR; Femring; Menoring) – estrogen (estrogen receptor agonist) – atrophic vaginitis [138]
  • Estriol succinate vaginal gel (6α-hydroxyestradiol; Blissel; Gelistrol) – estrogen (estrogen receptor agonist) – atrophic vaginitis [139]
  • Estriol/lactobacillus (estriol-Lactobcillus acidophilus mixt.; estriol/lyophilised lactobacilli; Gynoflor; ultra-low dose estrogen/lactobacillus) – combination of estriol (estrogen) and lactobacillus (probiotic) – atrophic vaginitis [140]
  • Ospemifene (FC-1271a; Ophena; Osphena; Senshio) – selective estrogen receptor modulator (SERM) – atrophic vaginitis, dyspareunia [141]

Other sex-hormonal agents

  • Prasterone vaginal (dehydroepiandrosterone; DHEA; Intrarosa; Vaginorm) – androgen (androgen receptor agonist), other actions – atrophic vaginitis, dyspareunia [142]
  • Testosterone propionate (TP; Synandrol; Synerone) – androgen (androgen receptor agonist) – decreased libido [143]
  • Tibolone (Livial) – androgen, estrogen, and progestogen – atrophic vaginitis, dyspareunia, low sexual desire [144][9][10][11][12]
  • Triptorelin (Arvekap; AY-25650; BIM-21003; BN-52014; CL-118532; Debio-8200; Debio-8206; debio8200; Decapeptyl; Decapeptyl SR; Decapeptyl LP; Diphereline; Gonapeptyl; Moapar; Pamorelin; Pamorelin LA; Salvacyl; Trelstar; Trelstar Depot; Triptodur; Triptoreline; Tryptorelin; WY-42422) – gonadotropin-releasing hormone (GnRH) receptor agonist – paraphilias [145]

Other drugs

  • Apomorphine (Ixense; Spontane; TAK-251; Uprima) – non-selective dopamine receptor agonist, other actions – erectile dysfunction [146]
  • Bremelanotide (Rekynda; Vyleesi; PT-141) – melanocortin MC4 receptor agonist – female sexual dysfunction [147]
  • Dapoxetine (LY-210448; LY210448; LY-210,448; Priligy) – selective serotonin reuptake inhibitor (SSRI) – premature ejaculation [148]
  • Flibanserin (Addyi; BIMT-17; BIMT-17-BS; Girosa) – serotonin 5-HT1A receptor agonist, serotonin 5-HT2A receptor antagonist, other actions – female sexual dysfunction [149]
  • Lidocaine/prilocaine (Fortacin; Prilocaine Lidocaine Plethora; prilocaine/lidocaine; PSD-502; Senstend; Tempe) – combination of lidocaine (sodium channel blocker, local anesthetic) and prilocaine (sodium channel blocker, local anesthetic) – premature ejaculation [150]
  • Moxisylyte (thymoxamine) – α1-adrenergic receptor antagonist – erectile dysfunction [13]
  • Papaverine (Pavabid) – phosphodiesterase PDE10A inhibitor, other actions – erectile dysfunction [14][15]
  • Phentolamine (Vasomax) – α1- and α2-adrenergic receptor antagonist – erectile dysfunction [16]

Combination drugs

  • Acecarbromal/quebracho/vitamin E (Afrodor) – various actions – erectile dysfunction [17]
  • Aviptadil/phentolamine (Invicorp; phentolamine/aviptadil; PSD-510; Vasopotin) – combination of aviptadil (vasoactive intestinal peptide (VIP) receptor agonist) and phentolamine (α-adrenergic receptor antagonist) – erectile dysfunction [151]
  • Papaverine/phentolamine – combination of papaverine (phosphodiesterase PDE10A inhibitor, other actions) and phentolamine (α-adrenergic recpetor antagonist) – erectile dysfunction [15]
  • Tadalafil/tamsulosin (Gugutams cap.; HCP-1303) – combination of tadalafil (phosphodiesterase PDE5 inhibitor) and tamsulosin (α1-adrenergic receptor antagonist) – erectile dysfunction [152]

Market withdrawal

  • Conjugated estrogens oral (Cenestin; synthetic conjugated estrogens) – estrogen (estrogen receptor agonist) – atrophic vaginitis [153]
  • Testosterone transdermal (Intrinsa; Intrinsa CHF; Livensa; Testosterone transdermal TheraDerm MTX; WC3048; WC3049) – androgen (androgen receptor agonist) – female sexual dysfunction [154]

Off-label drugs

Recreational drugs

See also: Party and play (chemsex)

See also

References

  1. ^ Nappi RE, Tiranini L, Cucinella L, Martini E, Bosoni D, Righi A, Cassani C, Gardella B (January 2023). "Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?". Expert Opin Pharmacother. 24 (1): 135–143. doi:10.1080/14656566.2022.2066997. PMID 35430926. Ovoca Bio (Dublin, Ireland) is currently developing Orenetide (BP-101), a novel synthetic peptide, as a potential nasal spray for first-in-class treatment to stimulate sexual motivation [88]. Experimental placebo-controlled data showed that acute intranasal BP101 administration moderately increased the frequency of solicitations, an indicator of sexual motivation in female rats, by acting within the hypothalamus under different hormonal conditions [93]. A Phase 2, multicenter, double-blind, randomized, placebo-controlled trial is ongoing in New Zealand and Australia to demonstrate the efficacy and safety of different doses of BP101 in premenopausal women with HSDD [89].
  2. ^ Both S (2017). "Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder". Curr Sex Health Rep. 9 (4): 192–199. doi:10.1007/s11930-017-0124-3. PMC 5711968. PMID 29225554.
  3. ^ Andreev-Andrievskiy A, Lomonosov M, Popova A, Lagereva E, Clément P, Salimov R, Golikov D (March 2017). "BP101 Peptide Promotes Female Sexual Receptivity in the Rat". J Sex Med. 14 (3): 336–346. doi:10.1016/j.jsxm.2017.01.008. PMID 28189563.
  4. ^ Sukhikh, Sukhikh G.T.; Smulevich, Smulevich A.B.; Stenyaeva, Stenyaeva N.N.; Nemenov D, Nemenov D.G.; Prilepskaya, Prilepskaya V.N.; Khritinin, Khritinin D.F.; Myasoedov, Myasoedov N.F.; Matskevich A, Matskevich A.A.; Andreeva, Andreeva L.A.; V, E.V. Zelenina E.V.; Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of the Russian Federation, Moscow, Russia; Psychiatric Hospital No. 1 named after N.A. Alexeev, Department of Health of Moscow, Russia, Moscow; IVIX Ltd., Moscow, Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia; Institute of Molecular Genetics of National Research Centre «Kurchatov Institute», Moscow, Russia (30 August 2022). "Orenetide for the treatment of hypoactive sexual desire disorder: results of a randomized placebo-controlled trial". Akusherstvo I Ginekologiia. 8_2022: 95–106. doi:10.18565/aig.2022.8.95-106. ISSN 2412-5679. Retrieved 27 January 2026.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: numeric names: authors list (link)
  5. ^ Royston A, Gray; Laura M N, Sahyoun; Michelle, Kokkinou; Fraser R, Boistelle; Ryan, Protzko; Nigel, Gericke; Thomas, Pfeiffer (6 July 2023). "(52) KH-001 BUT NOT OTHER TESTED ALKALOIDS DERIVED FROM SCELETIUM TORTUOSUM DELAYS EJACULATION IN THE RAT PARA-CHLOROAMPHETAMINE (PCA) MODEL". The Journal of Sexual Medicine. 20 (Supplement_4) qdad062.002. doi:10.1093/jsxmed/qdad062.002. ISSN 1743-6095. Retrieved 27 January 2026.
  6. ^ Dr Gruss, H; Protzko, R; Woodfinden, L; Boghossian, J; Koch, A (9 December 2025). "(059) First-in Human Study Investigating KH-001 Besylate as a Novel On-Demand Treatment for Premature Ejaculation: Pharmacokinetic and Safety Evaluation". The Journal of Sexual Medicine. 22 (Supplement_4) qdaf320.059. doi:10.1093/jsxmed/qdaf320.059. ISSN 1743-6095. Retrieved 27 January 2026.
  7. ^ "Novel compounds and uses thereof". Google Patents. 22 July 2022. Retrieved 27 January 2026.
  8. ^ McMahon CG (August 2016). "Emerging and investigational drugs for premature ejaculation". Transl Androl Urol. 5 (4): 487–501. doi:10.21037/tau.2016.04.02. PMC 5001989. PMID 27652222.
  9. ^ Albertazzi P, Di Micco R, Zanardi E (November 1998). "Tibolone: a review". Maturitas. 30 (3): 295–305. doi:10.1016/s0378-5122(98)00059-0. PMID 9881330.
  10. ^ Pinto-Almazán R, Segura-Uribe JJ, Farfán-García ED, Guerra-Araiza C (2017). "Effects of Tibolone on the Central Nervous System: Clinical and Experimental Approaches". Biomed Res Int. 2017 8630764. doi:10.1155/2017/8630764. PMC 5278195. PMID 28191467.
  11. ^ Biglia N, Maffei S, Lello S, Nappi RE (November 2010). "Tibolone in postmenopausal women: a review based on recent randomised controlled clinical trials". Gynecol Endocrinol. 26 (11): 804–814. doi:10.3109/09513590.2010.495437. PMID 20586550.
  12. ^ Garefalakis M, Hickey M (2008). "Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence". Clin Interv Aging. 3 (1): 1–8. doi:10.2147/cia.s1043. PMC 2544356. PMID 18488873.
  13. ^ Marquer C, Bressolle F (1998). "Moxisylyte: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in impotence". Fundam Clin Pharmacol. 12 (4): 377–387. doi:10.1111/j.1472-8206.1998.tb00961.x. PMID 9711459.
  14. ^ Rezaiezadeh H, Ranjbar Tavakoli M, Langarizadeh MA, Saeedi Garaghani Z, Karami-Mohajeri S (September 2024). "Unveiling the science behind erectile dysfunction topical therapy: investigating transdermal papaverine as a novel treatment approach". Sex Med Rev. 12 (4): 720–730. doi:10.1093/sxmrev/qeae059. PMID 39173091.
  15. ^ a b Zentgraf M, Baccouche M, Jünemann KP (1988). "Diagnosis and therapy of erectile dysfunction using papaverine and phentolamine". Urol Int. 43 (2): 65–75. doi:10.1159/000281308. PMID 3291360.
  16. ^ Goldstein I (March 2000). "Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction". Int J Impot Res. 12 Suppl 1: S75–80. doi:10.1038/sj.ijir.3900502. PMID 10845768.
  17. ^ Baumbusch F, Papp GK, Kopa ZS (1995). "Treatment for potency problems with Afrodor 2000". Acta Chir Hung. 35 (1–2): 87–92. PMID 8659243.
  18. ^ Jabir NR, Firoz CK, Zughaibi TA, Alsaadi MA, Abuzenadah AM, Al-Asmari AI, Alsaieedi A, Ahmed BA, Ramu AK, Tabrez S (December 2022). "A literature perspective on the pharmacological applications of yohimbine". Ann Med. 54 (1): 2861–2875. doi:10.1080/07853890.2022.2131330. PMC 9590431. PMID 36263866.
  19. ^ a b Corazza O, Martinotti G, Santacroce R, Chillemi E, Di Giannantonio M, Schifano F, Cellek S (2014). "Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba". Biomed Res Int. 2014 841798. doi:10.1155/2014/841798. PMC 4082836. PMID 25025070.
  20. ^ Tam SW, Worcel M, Wyllie M (September 2001). "Yohimbine: a clinical review". Pharmacol Ther. 91 (3): 215–243. doi:10.1016/s0163-7258(01)00156-5. PMID 11744068.
  21. ^ Morales A (August 2001). "Yohimbine in erectile dysfunction: would an orphan drug ever be properly assessed?". World J Urol. 19 (4): 251–255. doi:10.1007/s003450000182. PMID 11550783.
  22. ^ a b Cappelletti M, Wallen K (February 2016). "Increasing women's sexual desire: The comparative effectiveness of estrogens and androgens". Horm Behav. 78: 178–193. doi:10.1016/j.yhbeh.2015.11.003. PMC 4720522. PMID 26589379.
  23. ^ Khan O, Ferriter M, Huband N, Powney MJ, Dennis JA, Duggan C (February 2015). "Pharmacological interventions for those who have sexually offended or are at risk of offending". Cochrane Database Syst Rev. 2015 (2) CD007989. doi:10.1002/14651858.CD007989.pub2. PMC 6544815. PMID 25692326.
  24. ^ a b Assumpção AA, Garcia FD, Garcia HD, Bradford JM, Thibaut F (June 2014). "Pharmacologic treatment of paraphilias". Psychiatr Clin North Am. 37 (2): 173–181. doi:10.1016/j.psc.2014.03.002. PMID 24877704.
  25. ^ a b Guay DR (January 2009). "Drug treatment of paraphilic and nonparaphilic sexual disorders". Clin Ther. 31 (1): 1–31. doi:10.1016/j.clinthera.2009.01.009. PMID 19243704.
  26. ^ a b c Sajith SG, Morgan C, Clarke D (December 2008). "Pharmacological management of inappropriate sexual behaviours: a review of its evidence, rationale and scope in relation to men with intellectual disabilities". J Intellect Disabil Res. 52 (12): 1078–1090. doi:10.1111/j.1365-2788.2008.01097.x. PMID 18557968.
  27. ^ a b Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, Pfaus J, Simon JA, Kingsberg SA, Meston C, Stahl SM, Wallen K, Worsley R (January 2017). "Hypoactive Sexual Desire Disorder: International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review". Mayo Clin Proc. 92 (1): 114–128. doi:10.1016/j.mayocp.2016.09.018. PMID 27916394.
  28. ^ Razali NA, Sidi H, Choy CL, Roos NA, Baharudin A, Das S (2022). "The Role of Bupropion in the Treatment of Women with Sexual Desire Disorder: A Systematic Review and Meta-Analysis". Curr Neuropharmacol. 20 (10): 1941–1955. doi:10.2174/1570159X20666220222145735. PMC 9886814. PMID 35193485.
  29. ^ Pereira VM, Arias-Carrión O, Machado S, Nardi AE, Silva AC (2014). "Bupropion in the depression-related sexual dysfunction: a systematic review". CNS Neurol Disord Drug Targets. 13 (6): 1079–1088. doi:10.2174/1871527313666140612112630. PMID 24923342.
  30. ^ Demyttenaere K, Jaspers L (September 2008). "Review: Bupropion and SSRI-induced side effects". J Psychopharmacol. 22 (7): 792–804. doi:10.1177/0269881107083798. PMID 18308785.
  31. ^ Ginzburg R, Wong Y, Fader JS (December 2005). "Effect of bupropion on sexual dysfunction". Ann Pharmacother. 39 (12): 2096–2099. doi:10.1345/aph.1G275. PMID 16288071.
  32. ^ Wu PC, Hung CS, Kang YN, Wu CC (February 2021). "Tolerability and Optimal Therapeutic Dosage of Clomipramine for Premature Ejaculation: A Systematic Review and Meta-Analysis". Sex Med. 9 (1): 100283. doi:10.1016/j.esxm.2020.10.011. PMC 7930847. PMID 33291044.
  33. ^ Choi JB, Kang SH, Lee DH, Kim YS, Jeon JS, Choi WS, Kim SW (January 2019). "Efficacy and Safety of On Demand Clomipramine for the Treatment of Premature Ejaculation: A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial". J Urol. 201 (1): 147–152. doi:10.1016/j.juro.2018.07.089. PMID 30086277.
  34. ^ Javanbakht A (February 2015). "As-needed use of cyproheptadine for treatment of selective serotonin reuptake inhibitor-related female anorgasmia". J Clin Psychopharmacol. 35 (1): 91–93. doi:10.1097/JCP.0000000000000260. PMID 25502486.
  35. ^ Aizenberg D, Zemishlany Z, Weizman A (August 1995). "Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors". Clin Neuropharmacol. 18 (4): 320–324. doi:10.1097/00002826-199508000-00003. PMID 8665544.
  36. ^ Badr B, Naguy A (October 2022). "Cyproheptadine: a psychopharmacological treasure trove?". CNS Spectr. 27 (5): 533–535. doi:10.1017/S1092852921000250. PMID 33632345.
  37. ^ Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR (March 2016). "Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction". J Sex Med. 13 (3): 305–316. doi:10.1016/j.jsxm.2015.11.015. PMID 26944462.
  38. ^ Cucinella L, Cassani C, Martini E, Parrotta GE, Monne G, Colombo GM, Morteo V, Nappi RE (September 2025). "Sexual function after menopause: the role of vaginal estrogens". Maturitas. 200 108681. doi:10.1016/j.maturitas.2025.108681. PMID 40743861.
  39. ^ Auer MK, Joue G, Biedermann SV, Sommer T, Fuss J (February 2024). "The effect of short-term increase of estradiol levels on sexual desire and orgasm frequency in women and men: A double-blind, randomized, placebo-controlled trial". Psychoneuroendocrinology. 160 106682. doi:10.1016/j.psyneuen.2023.106682. PMID 38056372.
  40. ^ Clayton AH, Campbell BJ, Favit A, Yang Y, Moonsammy G, Piontek CM, Amsterdam JD (December 2007). "Symptoms of sexual dysfunction in patients treated for major depressive disorder: a meta-analysis comparing selegiline transdermal system and placebo using a patient-rated scale". J Clin Psychiatry. 68 (12): 1860–1866. doi:10.4088/jcp.v68n1205. PMID 18162016.
  41. ^ Martyn-St James M, Cooper K, Kaltenthaler E, Dickinson K, Cantrell A, Wylie K, Frodsham L, Hood C (January 2015). "Tramadol for premature ejaculation: a systematic review and meta-analysis". BMC Urol. 15 6. doi:10.1186/1471-2490-15-6. PMC 4417346. PMID 25636495.
  42. ^ Kirby EW, Carson CC, Coward RM (July 2015). "Tramadol for the management of premature ejaculation: a timely systematic review". Int J Impot Res. 27 (4): 121–127. doi:10.1038/ijir.2015.7. PMID 25971856.
  43. ^ Wong BL, Malde S (January 2013). "The use of tramadol "on-demand" for premature ejaculation: a systematic review". Urology. 81 (1): 98–103. doi:10.1016/j.urology.2012.08.037. PMID 23102445.
  44. ^ Yang L, Qian S, Liu H, Liu L, Pu C, Han P, Wei Q (2013). "Role of tramadol in premature ejaculation: a systematic review and meta-analysis". Urol Int. 91 (2): 197–205. doi:10.1159/000348826. PMID 23751284.
  45. ^ Sharma AP, Sharma G, Tyagi S, Devana SK, Mavuduru RS, Bora GS, Singh SK (2021). "Safety and efficacy of "on-demand" tramadol in patients with premature ejaculation: an updated meta-analysis". Int Braz J Urol. 47 (5): 921–934. doi:10.1590/S1677-5538.IBJU.2020.0561. PMC 8321462. PMID 33566469.
  46. ^ Wu T, Yue X, Duan X, Luo D, Cheng Y, Tian Y, Wang K (September 2012). "Efficacy and safety of tramadol for premature ejaculation: a systematic review and meta-analysis". Urology. 80 (3): 618–624. doi:10.1016/j.urology.2012.05.035. PMID 22840860.
  47. ^ Tan H, Zhou Z, Cui Y, Feng F, Zhang Y (November 2021). "A systematic review and meta-analysis of randomized controlled trials of "on-demand" use of tramadol vs "on-demand" use of paroxetine in the management of patients with premature ejaculation". Int J Clin Pract. 75 (11) e14825. doi:10.1111/ijcp.14825. PMID 34492139.
  48. ^ Pyke RE (April 2020). "Trazodone in Sexual Medicine: Underused and Overdosed?". Sex Med Rev. 8 (2): 206–216. doi:10.1016/j.sxmr.2018.08.003. PMID 30342856.
  49. ^ Fink HA, MacDonald R, Rutks IR, Wilt TJ (September 2003). "Trazodone for erectile dysfunction: a systematic review and meta-analysis". BJU Int. 92 (4): 441–446. doi:10.1046/j.1464-410x.2003.04358.x. PMID 12930437.
  50. ^ Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A (August 2012). "Off-label uses of trazodone: a review". Expert Opin Pharmacother. 13 (12): 1707–1717. doi:10.1517/14656566.2012.699523. PMID 22712761.
  51. ^ a b c d e f g Platteau, Tom; Schrooten, Jochen; Herrijgers, Corinne; den Daas, Chantal; Ventura, Mireia; Strong, Carol; de Wit, John (10 July 2025). "Polydrug use during chemsex: single and intersecting sexual effects of commonly used drugs". Frontiers in Public Health. 13 1618070. Bibcode:2025FrPH...1318070P. doi:10.3389/fpubh.2025.1618070. ISSN 2296-2565. PMC 12287032. PMID 40709041.
  52. ^ a b c d e f Giorgetti R, Tagliabracci A, Schifano F, Zaami S, Marinelli E, Busardò FP (2017). "When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex"". Curr Neuropharmacol. 15 (5): 762–770. doi:10.2174/1570159X15666161117151148. PMC 5771052. PMID 27855594.
  53. ^ a b c Le Bouëdec D, Pelletier R, Bénézit F, Pangui R, Morel I, Gicquel T (November 2025). "Chemsex, drugs and consequences: A short review". Therapie. doi:10.1016/j.therap.2025.11.006. PMID 41381266.
  54. ^ Georgiadis N, Katsimpris A, Vatmanidou MA, Vassilakou T, Beloukas A, Sergentanis TN (October 2025). "Prevalence of chemsex and sexualized drug use among men who have sex with men: A systematic review and meta-analysis". Drug Alcohol Depend. 275 112800. doi:10.1016/j.drugalcdep.2025.112800. PMID 40759067.
  55. ^ Tomkins A, George R, Kliner M (January 2019). "Sexualised drug taking among men who have sex with men: a systematic review". Perspect Public Health. 139 (1): 23–33. doi:10.1177/1757913918778872. PMID 29846139.
  56. ^ Trombley TA, Capstick RA, Lindsley CW (December 2020). "DARK Classics in Chemical Neuroscience: Gamma-Hydroxybutyrate (GHB)". ACS Chem Neurosci. 11 (23): 3850–3859. doi:10.1021/acschemneuro.9b00336. PMID 31287661.
  57. ^ Mostafa T, Alghobary MF (July 2022). "Recreational Use of Oral PDE5 Inhibitors: The Other Side of Midnight". Sex Med Rev. 10 (3): 392–402. doi:10.1016/j.sxmr.2021.10.004. PMID 34903486.
  58. ^ Palamar JJ, Acosta P (January 2020). "A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines". Hum Psychopharmacol. 35 (1) e2719. doi:10.1002/hup.2719. PMC 6995261. PMID 31909513.
  59. ^ Nolan, James (2019-03-05). "This Is What 2-CB Does to You". Vice.com. Archived from the original on 11 November 2020. Retrieved 2021-10-03.
  60. ^ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  61. ^ Shulgin, Alexander; Shulgin, Ann (September 1997). TiHKAL: The Continuation. Berkeley, California: Transform Press. ISBN 0-9630096-9-9. OCLC 38503252.
  62. ^ Araújo AM, Carvalho F, Bastos Mde L, Guedes de Pinho P, Carvalho M (August 2015). "The hallucinogenic world of tryptamines: an updated review" (PDF). Arch Toxicol. 89 (8): 1151–1173. Bibcode:2015ArTox..89.1151A. doi:10.1007/s00204-015-1513-x. PMID 25877327. Some studies also revealed that the use of tryptamine derivatives, especially of 5-MeO-DIPT, has come up very frequent among homosexual drug users (Clatts et al. 2005; Lee et al. 2013; Wada et al. 2013).
  63. ^ Moyle L, Dymock A, Aldridge A, Mechen B (December 2020). "Pharmacosex: Reimagining sex, drugs and enhancement". Int J Drug Policy. 86 102943. doi:10.1016/j.drugpo.2020.102943. PMC 7773803. PMID 33246312. Range of drugs and types of use [...] The same substances were broadly found as most commonly cited as enhancing sex in the virtual ethnography, although other substances, which interview participants sometimes lamented were difficult to access, included novel psychoactive substances such as 5-MeO-DIPT ('Foxy Methoxy').
  64. ^ Miwa T, Strong C, Hayashi K, Yamaguchi M, Wakabayashi C, Ikushima Y (July 2025). "Drug Dependence Severity and Associated Factors Among Cisgender Gay, Bisexual and Other Men Who Have Sex With Men in Japan". J Psychoactive Drugs: 1–10. doi:10.1080/02791072.2025.2537044. PMID 40697137.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.